Related Experiment Videos
Failure of allopurinol to modify urinary composition in enteric hyperoxaluria
D P D'Cruz1, D J Gertner, G P Kasidas
1Department of Medicine, Newham General Hospital, London.
British Journal of Urology
|September 1, 1989
Summary
Allopurinol did not reduce urinary oxalate excretion in patients with enteric hyperoxaluria (EHO). This study suggests allopurinol is unlikely to prevent kidney stones in EHO patients.
Area of Science:
- Nephrology
- Gastroenterology
- Urology
Background:
- Enteric hyperoxaluria (EHO) management involves dietary changes and treating underlying causes.
- Allopurinol has shown promise in reducing urolithiasis and oxalate excretion in patients without intestinal disease.
Purpose of the Study:
- To assess the efficacy of allopurinol in altering urine biochemistry in EHO patients with small bowel Crohn's disease or resections.
Main Methods:
- Patients received allopurinol (300 mg daily) for 2 weeks.
- Urine and plasma biochemistry were analyzed to confirm compliance and assess changes.
- Key analytes included oxalate, uric acid, glycollate, citrate, magnesium, and calcium.
Main Results:
- Allopurinol compliance was confirmed by decreased plasma uric acid levels.
- No significant changes were observed in 24-hour urinary oxalate excretion or concentration.
- Urinary excretion of glycollate, citrate, magnesium, and calcium remained unchanged.
Conclusions:
- Allopurinol is unlikely to be beneficial in preventing urolithiasis in patients suffering from EHO.
- Further research may be needed to explore alternative treatments for EHO-related kidney stone prevention.